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PMH28
COST-EFFECTIVENESS OF INTERVENTIONS TO IMPROVE
PATIENT MEDICATON COMPLIANCE IN MAJOR DEPRESSIVE
DISORDER
Setyawan J, Hay JW, Nichol MB
University of Southern California, Los Angeles, CA, USA
OBJECTIVES: To determine the CEA of three alternative inter-
ventions to improve patient medication compliance in major
depressive disorder (MDD). METHODS: Decision tree analysis
from the societal perspective was employed to determine the
CEA of several interventions to improve medication compliance.
The three relevant alternatives were: psychiatrist + primary care
provider (PCP) + antidepressant (Rx); psychologist + PCP + Rx;
or PCP + Rx (Usual care). Two sets of CEA were conducted,
including program set-up costs and excluding program set-up
costs. The target population was patients with MDD between 20
to 30 years in USA. The time horizon was 12 months. Thus, total
costs incurred were estimated for the entire 12 months and no
discounting was applied to the numerator. A 3% discount 
rate was applied to the QALYs to account for the lost of life
expectancy due to suicide. One-way sensitivity analyses were
done. RESULTS: Both intervention alternatives that utilize either
psychiatrists or psychologists are dominant strategies relative to
usual care. Analysis with inclusion of program set-up costs
demonstrates that, the ICER for psychiatrist vs. psychologist is
$3860. For the analysis excluding program set-up costs, the
ICER for psychiatrist vs. psychologist is $5038. The model is
robust, and most sensitive to variation in daily time spent by
caregivers. CONCLUSIONS: Intervention to improve medica-
tion compliance in MDD is a dominant strategy over the current
standard of practice, thus should be advocated. When viewed
from the societal perspective, the intervention utilizing psychia-
trists is cost-effective and should be implemented.
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OBJECTIVES: Depression, especially severe depression, is a
mental disorder that presents an enormous economic burden to
individuals and to society. Our objective was to determine the
cost-effectiveness of escitalopram compared with catalpa in the
management of severe depression [Montgomery-As berg Depres-
sion Rating Scale (MADRS) score ≥ 30] in Austria. METHODS:
A decision analytic model with a 6-month time horizon was
adapted from Brown et al. (1999). The model incorporated treat-
ment paths and associated direct resource use (psychiatric hos-
pitalisations, medications, GP and psychiatrist visits, treatment
discontinuation and attempted suicide) associated with the treat-
ment of severe depression and the indirect cost due to work
absenteeism. Main outcomes were clinical success (remission at
6 months) and cost (2002 Euros) of treatment. The analysis was
performed from the Austrian societal and Social Health care
Insurance System (SHIS) perspectives. Clinical input data were
derived from a meta-analysis of 8-week head-to-head ran-
domised clinical trials. Costs were derived from standard Aus-
trian price lists or from the literature. Societal costs of lost
productivity were calculated using the Human Capital approach.
RESULTS: At 6 months after start of treatment, the overall clin-
ical success remission rate was higher for escitalopram (53.7%)
than for catalpa (48.7%). From the SHIS perspective, the total
expected cost per successfully treated patient was 924€ (32.1%)
lower for escitalopram (2879€) compared with catalpa (3803€).
From the societal perspective, the total expected cost per suc-
cessfully treated severely depressed patient was 1369€ (24.4%)
lower for escitalopram (5610€) than for catalpa (6979€). Sensi-
tivity analyses demonstrated that the model was robust and that
even if catalpa had an acquisition cost of 0€, escitalopram
remained the dominant strategy for both perspectives. CON-
CLUSION: Treatment with escitalopram was the dominant
strategy. The results of this study suggest that escitalopram is a
cost-effective antidepressant compared with catalpa in the man-
agement of severe depression in Austria.
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